JP2002542341A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002542341A5 JP2002542341A5 JP2000611949A JP2000611949A JP2002542341A5 JP 2002542341 A5 JP2002542341 A5 JP 2002542341A5 JP 2000611949 A JP2000611949 A JP 2000611949A JP 2000611949 A JP2000611949 A JP 2000611949A JP 2002542341 A5 JP2002542341 A5 JP 2002542341A5
- Authority
- JP
- Japan
- Prior art keywords
- formulation
- lipid
- compound
- group
- peg
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 description 51
- 150000001875 compounds Chemical class 0.000 description 48
- 150000002632 lipids Chemical group 0.000 description 40
- 238000009472 formulation Methods 0.000 description 38
- 229920001223 polyethylene glycol Polymers 0.000 description 20
- 239000013583 drug formulation Substances 0.000 description 14
- 238000000034 method Methods 0.000 description 10
- 239000012867 bioactive agent Substances 0.000 description 8
- -1 phospho Chemical class 0.000 description 8
- 229920000642 polymer Polymers 0.000 description 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 5
- 229920001477 hydrophilic polymer Polymers 0.000 description 5
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 4
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical group C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 4
- 229920000954 Polyglycolide Polymers 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 125000000217 alkyl group Chemical group 0.000 description 4
- 150000001408 amides Chemical class 0.000 description 4
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 4
- AEOCXXJPGCBFJA-UHFFFAOYSA-N ethionamide Chemical compound CCC1=CC(C(N)=S)=CC=N1 AEOCXXJPGCBFJA-UHFFFAOYSA-N 0.000 description 4
- 125000000524 functional group Chemical group 0.000 description 4
- 230000002163 immunogen Effects 0.000 description 4
- 108020004707 nucleic acids Proteins 0.000 description 4
- 150000007523 nucleic acids Chemical class 0.000 description 4
- 102000039446 nucleic acids Human genes 0.000 description 4
- 229920000747 poly(lactic acid) Polymers 0.000 description 4
- 239000004633 polyglycolic acid Substances 0.000 description 4
- 239000004626 polylactic acid Substances 0.000 description 4
- 238000001890 transfection Methods 0.000 description 4
- 241000726103 Atta Species 0.000 description 3
- 239000004952 Polyamide Substances 0.000 description 3
- 229940024606 amino acid Drugs 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 125000002091 cationic group Chemical group 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- 229920002647 polyamide Polymers 0.000 description 3
- 230000000087 stabilizing effect Effects 0.000 description 3
- 239000004475 Arginine Substances 0.000 description 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
- 125000002252 acyl group Chemical group 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 229960001230 asparagine Drugs 0.000 description 2
- 235000009582 asparagine Nutrition 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 210000004088 microvessel Anatomy 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 108010092160 Dactinomycin Proteins 0.000 description 1
- OOFLZRMKTMLSMH-UHFFFAOYSA-N H4atta Chemical compound OC(=O)CN(CC(O)=O)CC1=CC=CC(C=2N=C(C=C(C=2)C=2C3=CC=CC=C3C=C3C=CC=CC3=2)C=2N=C(CN(CC(O)=O)CC(O)=O)C=CC=2)=N1 OOFLZRMKTMLSMH-UHFFFAOYSA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical group C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 229940045799 anthracyclines and related substance Drugs 0.000 description 1
- 229940034982 antineoplastic agent Drugs 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 229960000640 dactinomycin Drugs 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 150000003058 platinum compounds Chemical class 0.000 description 1
- 125000000561 purinyl group Chemical class N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- 239000000277 virosome Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13015199P | 1999-04-20 | 1999-04-20 | |
| US60/130,151 | 1999-04-20 | ||
| PCT/CA2000/000451 WO2000062813A2 (en) | 1999-04-20 | 2000-04-20 | Cationic peg-lipids and methods of use |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012017765A Division JP2012122075A (ja) | 1999-04-20 | 2012-01-31 | カチオン性ｐｅｇ脂質および使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2002542341A JP2002542341A (ja) | 2002-12-10 |
| JP2002542341A5 true JP2002542341A5 (enExample) | 2007-06-07 |
| JP5117648B2 JP5117648B2 (ja) | 2013-01-16 |
Family
ID=22443303
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000611949A Expired - Fee Related JP5117648B2 (ja) | 1999-04-20 | 2000-04-20 | カチオン性ｐｅｇ脂質および使用方法。 |
| JP2012017765A Pending JP2012122075A (ja) | 1999-04-20 | 2012-01-31 | カチオン性ｐｅｇ脂質および使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012017765A Pending JP2012122075A (ja) | 1999-04-20 | 2012-01-31 | カチオン性ｐｅｇ脂質および使用方法 |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP1173600A2 (enExample) |
| JP (2) | JP5117648B2 (enExample) |
| AU (1) | AU783647B2 (enExample) |
| CA (1) | CA2370690A1 (enExample) |
| WO (1) | WO2000062813A2 (enExample) |
Families Citing this family (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2289702C (en) | 1997-05-14 | 2008-02-19 | Inex Pharmaceuticals Corp. | High efficiency encapsulation of charged therapeutic agents in lipid vesicles |
| US7189705B2 (en) | 2000-04-20 | 2007-03-13 | The University Of British Columbia | Methods of enhancing SPLP-mediated transfection using endosomal membrane destabilizers |
| WO2001080900A2 (en) * | 2000-04-20 | 2001-11-01 | The University Of British Columbia | Enhanced stabilised plasmid-lipid particle-mediated transfection using endosomal membrane |
| EP1328254B1 (en) * | 2000-10-25 | 2007-02-21 | The University Of British Columbia | Lipid formulations for target delivery |
| US6610322B1 (en) * | 2000-12-20 | 2003-08-26 | Brian Charles Keller | Self forming, thermodynamically stable liposomes and their applications |
| EP1519714B1 (en) | 2002-06-28 | 2010-10-20 | Protiva Biotherapeutics Inc. | Method and apparatus for producing liposomes |
| WO2004082626A2 (en) * | 2003-03-18 | 2004-09-30 | Ethicon, Inc. | Aromatase inhibitor diagnosis and therapy |
| AU2004257373B2 (en) | 2003-07-16 | 2011-03-24 | Arbutus Biopharma Corporation | Lipid encapsulated interfering RNA |
| CN1882693B (zh) * | 2003-09-15 | 2012-08-15 | 普洛体维生物治疗公司 | 聚乙二醇修饰的脂质化合物及其应用 |
| FR2870741B1 (fr) | 2004-05-25 | 2008-03-14 | Coletica Sa | Phase lamellaires hydratees ou liposomes, contenant une monoamine grasse ou un polymere cationique favorisant la penetration intercellulaire, et composition cosmetique ou pharmaceutique la contenant. |
| CA2569664C (en) | 2004-06-07 | 2013-07-16 | Protiva Biotherapeutics, Inc. | Lipid encapsulated interfering rna |
| WO2007028341A1 (fr) * | 2005-09-09 | 2007-03-15 | Beijing Diacrid Medical Technology Co., Ltd. | Nanomicelles servant de medicaments anticancereux a polyethylene phospholipides glycolyles contenant des vinca alcaloides |
| EP1948674A4 (en) | 2005-11-02 | 2009-02-04 | Protiva Biotherapeutics Inc | MODIFIED SIRNA MOLECULES AND APPLICATIONS THEREOF |
| US8877206B2 (en) * | 2007-03-22 | 2014-11-04 | Pds Biotechnology Corporation | Stimulation of an immune response by cationic lipids |
| US9006191B2 (en) | 2007-12-27 | 2015-04-14 | Protiva Biotherapeutics, Inc. | Silencing of polo-like kinase expression using interfering RNA |
| EP2279254B1 (en) | 2008-04-15 | 2017-07-05 | Protiva Biotherapeutics Inc. | Novel lipid formulations for nucleic acid delivery |
| WO2009129319A2 (en) | 2008-04-15 | 2009-10-22 | Protiva Biotherapeutics, Inc. | Silencing of csn5 gene expression using interfering rna |
| AU2009236306B2 (en) | 2008-04-17 | 2015-04-02 | Pds Biotechnology Corporation | Stimulation of an immune response by enantiomers of cationic lipids |
| EP3699172A3 (en) | 2008-11-10 | 2020-11-18 | Arbutus Biopharma Corporation | Novel lipids and compositions for the delivery of therapeutics |
| US9018187B2 (en) | 2009-07-01 | 2015-04-28 | Protiva Biotherapeutics, Inc. | Cationic lipids and methods for the delivery of therapeutic agents |
| US8569256B2 (en) | 2009-07-01 | 2013-10-29 | Protiva Biotherapeutics, Inc. | Cationic lipids and methods for the delivery of therapeutic agents |
| ES2613498T3 (es) | 2009-07-01 | 2017-05-24 | Protiva Biotherapeutics Inc. | Nuevas formulaciones de lípidos para el suministro de agentes terapéuticos a tumores sólidos |
| WO2011011447A1 (en) | 2009-07-20 | 2011-01-27 | Protiva Biotherapeutics, Inc. | Compositions and methods for silencing ebola virus gene expression |
| WO2011038160A2 (en) | 2009-09-23 | 2011-03-31 | Protiva Biotherapeutics, Inc. | Compositions and methods for silencing genes expressed in cancer |
| SI2506857T1 (en) | 2009-12-01 | 2018-08-31 | Translate Bio, Inc. | Delivery of mRNA for the enrichment of proteins and enzymes in human genetic diseases |
| US10077232B2 (en) | 2010-05-12 | 2018-09-18 | Arbutus Biopharma Corporation | Cyclic cationic lipids and methods of use |
| US20130123338A1 (en) | 2010-05-12 | 2013-05-16 | Protiva Biotherapeutics, Inc. | Novel cationic lipids and methods of use thereof |
| JP2013530187A (ja) | 2010-06-17 | 2013-07-25 | ザ ユナイテッド ステイツ オブ アメリカ アズ リプレゼンティッド バイ ザ シークレタリー デパートメント オブ ヘルス アンド ヒューマン サービシーズ | 炎症性疾患を治療するための組成物及び方法。 |
| US9006417B2 (en) | 2010-06-30 | 2015-04-14 | Protiva Biotherapeutics, Inc. | Non-liposomal systems for nucleic acid delivery |
| KR20220025112A (ko) | 2011-06-08 | 2022-03-03 | 샤이어 휴먼 지네틱 테라피즈 인크. | Mrna 전달을 위한 지질 나노입자 조성물 및 방법 |
| US11073451B2 (en) | 2011-12-19 | 2021-07-27 | Kode Biotech Limited | Biocompatible method of functionalising substrates with inert surfaces |
| US9035039B2 (en) | 2011-12-22 | 2015-05-19 | Protiva Biotherapeutics, Inc. | Compositions and methods for silencing SMAD4 |
| US9352042B2 (en) | 2012-02-24 | 2016-05-31 | Protiva Biotherapeutics, Inc. | Trialkyl cationic lipids and methods of use thereof |
| AU2013231638B2 (en) * | 2012-03-16 | 2017-10-12 | Merck Patent Gmbh | Targeting aminoacid lipids |
| EP3536787A1 (en) | 2012-06-08 | 2019-09-11 | Translate Bio, Inc. | Nuclease resistant polynucleotides and uses thereof |
| US10286064B2 (en) | 2012-06-15 | 2019-05-14 | Pds Biotechnology Corporation | Cationic lipid vaccine compositions and methods of use |
| AU2013317805B2 (en) | 2012-09-21 | 2018-07-26 | Pds Biotechnology Corporation | Improved vaccine compositions and methods of use |
| EA201591229A1 (ru) | 2013-03-14 | 2016-01-29 | Шир Хьюман Дженетик Терапис, Инк. | Способы очистки матричной рнк |
| KR102311614B1 (ko) | 2013-03-14 | 2021-10-08 | 샤이어 휴먼 지네틱 테라피즈 인크. | Cftr mrna 조성물 및 관련 방법 및 사용 |
| WO2015011633A1 (en) | 2013-07-23 | 2015-01-29 | Protiva Biotherapeutics, Inc. | Compositions and methods for delivering messenger rna |
| EP3574923A1 (en) | 2013-10-22 | 2019-12-04 | Translate Bio, Inc. | Mrna therapy for phenylketonuria |
| ES2707966T3 (es) | 2013-10-22 | 2019-04-08 | Translate Bio Inc | Terapia de ARNm para la deficiencia en síntesis de argininosuccinato |
| EP4729528A3 (en) | 2014-04-25 | 2026-06-24 | Translate Bio, Inc. | Methods for purification of messenger rna |
| US10415037B2 (en) | 2014-10-02 | 2019-09-17 | Arbutus Biopharma Corporation | Compositions and methods for silencing hepatitis B virus gene expression |
| WO2016197132A1 (en) | 2015-06-04 | 2016-12-08 | Protiva Biotherapeutics Inc. | Treating hepatitis b virus infection using crispr |
| CN108350455A (zh) | 2015-07-29 | 2018-07-31 | 阿布特斯生物制药公司 | 用于使b型肝炎病毒基因表达沉默的组合物和方法 |
| MX2018002090A (es) | 2015-08-24 | 2018-09-12 | Halo Bio Rnai Therapeutics Inc | Nanoparticulas de polinucleótido para modulación de expresión génica y sus usos. |
| US11612652B2 (en) | 2015-11-13 | 2023-03-28 | Pds Biotechnology Corporation | Lipids as synthetic vectors to enhance antigen processing and presentation ex-vivo in dendritic cell therapy |
| US11191849B2 (en) | 2016-06-30 | 2021-12-07 | Arbutus Biopharma Corporation | Compositions and methods for delivering messenger RNA |
| WO2018039131A1 (en) | 2016-08-22 | 2018-03-01 | Protiva Biotherapeutics, Inc. | Anti-pd-1 antibodies, or fragments thereof, for treating hepatitis b |
| AU2017379901B2 (en) | 2016-12-21 | 2024-02-15 | Arbutus Biopharma Corporation | Methods for ameliorating infusion reactions |
| MX2019010155A (es) | 2017-02-27 | 2020-12-10 | Translate Bio Inc | Arnm de cftr optimizado por codón novedoso. |
| IL270631B2 (en) | 2017-05-16 | 2024-03-01 | Translate Bio Inc | Treatment of cystic fibrosis by delivery of codon-optimized mrna encoding cftr |
| TW201924722A (zh) | 2017-12-05 | 2019-07-01 | 美商Ｐｄｓ生技公司 | 用於刺激第i型干擾素基因之方法及包含陽離子脂質的組合物 |
| US11174500B2 (en) | 2018-08-24 | 2021-11-16 | Translate Bio, Inc. | Methods for purification of messenger RNA |
| AU2019384557B2 (en) | 2018-11-21 | 2025-07-17 | Translate Bio, Inc. | Treatment of cystic fibrosis by delivery of nebulized mRNA encoding CFTR |
| GB201910299D0 (en) | 2019-07-18 | 2019-09-04 | Aouadi Myriam | Medical uses, methods and uses |
| CA3155003A1 (en) | 2019-09-20 | 2021-03-25 | Translate Bio, Inc. | Mrna encoding engineered cftr |
| KR102650691B1 (ko) * | 2019-12-20 | 2024-03-25 | 주식회사 삼양홀딩스 | 폴리락트산염을 포함하는 약물전달용 나노입자 조성물 제조용 키트 |
| JP7709981B2 (ja) | 2020-03-17 | 2025-07-17 | ジェネヴァント サイエンシズ ゲーエムベーハー | 肝星細胞への治療薬の脂質ナノ粒子送達のためのカチオン性脂質 |
| CN117098541A (zh) | 2020-11-25 | 2023-11-21 | 阿卡格拉医药公司 | 用于递送核酸的脂质纳米粒及相关使用方法 |
| KR20240146674A (ko) | 2022-01-31 | 2024-10-08 | 제네반트 사이언시즈 게엠베하 | 지질 나노입자를 위한 이온화 가능한 양이온성 지질 |
| WO2023230587A2 (en) | 2022-05-25 | 2023-11-30 | Akagera Medicines, Inc. | Lipid nanoparticles for delivery of nucleic acids and methods of use thereof |
| WO2024214632A1 (ja) * | 2023-04-14 | 2024-10-17 | 国立大学法人 東京大学 | ホスホニウム基を有するカチオン性ポリマーおよびこれを含むポリマー粒子または医薬組成物 |
| WO2025052278A1 (en) | 2023-09-05 | 2025-03-13 | Genevant Sciences Gmbh | Pyrrolidine based cationic lipids for lipid nanoparticle delivery of therapeutics to hepatic stellate cells |
| WO2025158420A1 (en) | 2024-01-25 | 2025-07-31 | Nanocell Therapeutics Holdings B.V. | Methods and composition for inducing activation and dna expression in t-cells |
| WO2025169168A1 (en) | 2024-02-09 | 2025-08-14 | Nanocell Therapeutics Holdings B.V. | Extracorporeal transfection of immune effector cells |
| WO2026159700A1 (en) | 2025-01-27 | 2026-07-30 | Nanocell Therapeutics Holdings B.V. | Methods and composition for inducing activation and dna expression in t-cells |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2218541A1 (en) * | 1995-06-07 | 1996-12-19 | Imarx Pharmaceutical Corp. | Novel targeted compositions for diagnostic and therapeutic use |
| TW520297B (en) * | 1996-10-11 | 2003-02-11 | Sequus Pharm Inc | Fusogenic liposome composition and method |
| WO1998016201A1 (en) * | 1996-10-11 | 1998-04-23 | Sequus Pharmaceuticals, Inc. | Therapeutic liposome composition and method |
| WO1998046208A1 (en) * | 1997-04-17 | 1998-10-22 | The Regents Of The University Of Michigan | Hair follicle dna delivery system |
| AU7490098A (en) * | 1997-05-15 | 1998-12-08 | Genzyme Corporation | Cationic amphiphile formulations |
| US6395713B1 (en) * | 1997-07-23 | 2002-05-28 | Ribozyme Pharmaceuticals, Inc. | Compositions for the delivery of negatively charged molecules |
| WO1999005303A1 (en) * | 1997-07-24 | 1999-02-04 | Inex Pharmaceuticals Corporation | Preparation of lipid-nucleic acid particles using a solvent extraction and direct hydration method |
| CA2335638A1 (en) * | 1998-06-19 | 1999-12-23 | Ronald K. Scheule | Cationic amphiphile micellar complexes |
| CA2358497A1 (en) * | 1999-01-21 | 2000-07-27 | Georgetown University | Ligand-peg post-coating stabilized lipoplex and polyplex for targeted gene delivery |
| EP1046394A3 (en) * | 1999-04-19 | 2001-10-10 | ImaRx Pharmaceutical Corp. | Novel compositions useful for delivering compounds into a cell |
| DE60130741T2 (de) * | 2000-03-02 | 2008-07-03 | Mitsubishi Pharma Corp. | GPib-GEBUNDENES KONSTRUKT UND VERWENDUNGEN DAVON |
-
2000
- 2000-04-20 WO PCT/CA2000/000451 patent/WO2000062813A2/en not_active Ceased
- 2000-04-20 AU AU40962/00A patent/AU783647B2/en not_active Ceased
- 2000-04-20 EP EP00920309A patent/EP1173600A2/en not_active Withdrawn
- 2000-04-20 JP JP2000611949A patent/JP5117648B2/ja not_active Expired - Fee Related
- 2000-04-20 CA CA002370690A patent/CA2370690A1/en not_active Abandoned
-
2012
- 2012-01-31 JP JP2012017765A patent/JP2012122075A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102198736B1 (ko) | 생체 내 약물 전달을 위한 지질 나노입자 및 이의 용도 | |
| Jeong et al. | Poly (L-lysine)-g-poly (D, L-lactic-co-glycolic acid) micelles for low cytotoxic biodegradable gene delivery carriers | |
| EP0789564B1 (en) | Polynucleotide compositions | |
| US8324365B2 (en) | Conjugate for gene transfer comprising oligonucleotide and hydrophilic polymer, polyelectrolyte complex micelles formed from the conjugate, and methods for preparation thereof | |
| US6440743B1 (en) | Methods of using polynucleotide compositions | |
| US8182802B2 (en) | Composition of polymers | |
| Nicolazzi et al. | Anionic polyethyleneglycol lipids added to cationic lipoplexes increase their plasmatic circulation time | |
| EP2042184B1 (en) | Physiologically active polypeptide, polymer micelle having protein enclosed therein, and process for production of the polymer micelle | |
| CA2717370A1 (en) | Biodegradable cross-linked branched poly (alkylene imines) | |
| WO1999006055A1 (en) | Polynucleotide compositions | |
| US20210393523A1 (en) | Aromatic ring substituted amphiphilic polymers as drug delivery systems | |
| JPWO2020116640A1 (ja) | 薬物複合体、ポリマー複合体及び薬物送達用組成物 | |
| CN116367841A (zh) | 用于治疗病毒性疾病的含有核苷的siRNA | |
| JP2009542582A5 (enExample) | ||
| JP2004508012A (ja) | エンドソーム膜不安定剤を用いたｓｐｌｐ媒介性トランスフェクションの強化方法 | |
| ES2270171T3 (es) | Polimeros tribloques para la administracion de un agente o de un medicamento a base de nanosferas. | |
| JP2004515228A (ja) | 細胞への導入を容易にするジェミニ型のペプチド系界面活性化合物 | |
| Sideratou et al. | Design of functional dendritic polymers for application as drug and gene delivery systems | |
| US12064512B2 (en) | Silyl lipids suitable for enhanced delivery of anti-viral therapeutics | |
| EP1003527A1 (en) | Polynucleotide compositions | |
| WO2025024773A2 (en) | Diblock copolymer-mediated lipid nanoparticles | |
| EP4622673A1 (en) | Novel carriers for nucleic acid and/or protein delivery | |
| Uglea et al. | Dendrimers: A New Tool for Drug Administration | |
| AU1498100A (en) | Polynucleotide compositions |